Alpelisib-Piqray How many boxes per month

Alpelisib (Piqray) - Piqray is approved for the treatment of hormone receptor-positive but HER2-negative breast cancer with a mutation in the PIK3CA gene. It is used with fulvestrant to treat postmenopausal women and men whose breast cancer is advanced or metastatic and has progressed during or after hormone therapy. Apelvis is also being studied in the treatment of other types of cancer.

Apelix is available only by prescription and should be administered under the guidance and supervision of a physician experienced in the use of cancer drugs. Apelis is available in tablet form and is taken orally immediately after a meal. The recommended dose is 300 mg once daily at the same time at the same time. Treatment should be continued for as long as the patient benefits from it. If a patient experiences unacceptable side effects, the doctor may stop treatment or reduce the dose. The European version of Apelix has a specification of 150mg*56 tablets per box. It is estimated that a patient may need about one box for a month. The Indian version has a specification of 150mg*28 tablets per box. It is estimated that a patient may need about two boxes for a month.

The original drug of Apellis is not marketed in the country and therefore cannot be included in medical insurance. The original Apelix drug sold overseas has a European version and an Indian version, and their ingredients are basically the same. The price of each box of the European version may be more than 4 RMB (the price may fluctuate due to the exchange rate), while the price of the Indian version may be more than more than RMB (the price may fluctuate due to the exchange rate). At present, there are no generic drugs of Apellis on the market. Please consult your medical consultant for specific prices and drug information of Apelis.